Pluristem Partners With CPC Clinical Research for Peripheral Artery Disease Study

HAIFA, Israel -- Pluristem Therapeutics, Inc. , today announced that in anticipation of initiating a Phase II study using PLX-PAD cells for the treatment of Intermittent Claudication (IC), the company ...